The U.S. economy unexpectedly added 2.5 million payrolls in May. Allianz Chief Economic Adviser Mohamed El-Erian joins Yahoo Finance’s On The Move to weigh in on the latest jobs report.

from Yahoo Finance https://ift.tt/2ALgxEg

Trump’s handling of the pandemic received a mixed review from Chase Koch, the president of venture capital firm Koch Disruptive Technologies and son of Charles Koch, the multi-billionaire CEO of Koch Industries and one of the nation’s most influential conservative political donors.

from Yahoo Finance https://ift.tt/2YazLLc

The Schork Report Editor Stephen Schork joins Yahoo Finance’s Zack Guzman to discuss the latest outlook for oil and gas ahead of the upcoming OPEC+ meeting.

from Yahoo Finance https://ift.tt/3f0GI8r

Mark Bertolini is calling for investing in workers, education, and taking a holistic approach to healthcare as the path forward to restoring the American dream, and fixing capitalism.

from Yahoo Finance https://ift.tt/3eTnqC7

The date of Fannie Mae‘s conservatorship release has long been a topic of interest, and it’s become even more so of interest as the date approaches. Experts debate how much of an impact the coronavirus pandemic had on the date when Fannie Mae and Freddie Mac will be released from conservatorship. Moving toward Fannie Mae, Freddie […]

from Yahoo Finance https://ift.tt/2Yg3LWq

Oil prices jumped on Friday after OPEC+ decided to move up its meeting on extending production cuts. KPMG Global Head of Energy Regina Mayor joins Yahoo Finance’s On The Move panel to assess the state of oil markets.

from Yahoo Finance https://ift.tt/2Yd6Lm6

Hindenburg Research on Genius Brands Since early May, and even accounting for yesterday’s plunge, shares of small TV production company Genius Brands International Inc (NASDAQ:GNUS) have appreciated in value by more than 20x on relatively mundane news. We think the stock will drop as quickly as it skyrocketed. The company itself appears to agree with us, believing its […]

from Yahoo Finance https://ift.tt/378LWfK

PowerSchool is an online leading provider of K-12 education. PowerSchool CEO Hardeep Gulati joins Yahoo Finance’s On The Move panel to break down how kids have adapted to learning online amid the COVID-19 pandemic.

from Yahoo Finance https://ift.tt/377tOD2

UK-based pharmaceutical company AstraZeneca Plc (AZN) is reportedly interested in a potential merger with rival drugmaker Gilead Sciences Inc. (GILD) in what would be the biggest health-care deal on record.Bloomberg reported on Sunday that AstraZeneca informally contacted Gilead last month to show its interest in a possible deal. The pharmaceutical company didn’t specify terms for any transaction, which if successful would tie together two companies advancing the development of a vaccine against COVID-19.According to the report, Gilead has discussed a potential deal with advisers, but no decisions have been made on how to proceed and the companies aren’t in formal talks.AstraZeneca, valued at $140 billion, is the U.K.’s biggest drugmaker by market capitalization and has developed treatments from cancer to cardiovascular disease. On Thursday, the drugmaker said that it signed supply chain deals for the capacity to produce 2 billion doses of its potential coronavirus vaccine, which it is developing with Oxford University.Gilead is not currently interested in selling to or merging with another big pharmaceutical company and prefers instead to focus its deal strategy on partnerships and smaller acquisitions, the report said. The company, worth $96 billion at Friday’s close, is the creator of the investigational antiviral remdesivir, which has received U.S. approval for use with hospitalized patients with severe COVID-19, but this authorization is only temporary.Shares in Gilead have this year advanced 18% as investors have been closely following developments of its antiviral drug for Covid-19 through clinical trials. The stock, which fell 1% to trade at $76.75 on Friday, is still far off its highs seen in 2015.Leerink Partners analyst Geoff Porges last week upgraded the company’s stock to Buy from Hold with a $94 price target (22% upside potential), saying that he forecasts remdesivir sales may reach $7.7 billion in 2022.Porges is also upbeat about Gilead’s recent investment in Arcus Biosciences Inc., which he believes gives the drugmaker "critical mass in oncology"."With these additional opportunities we believe a valuation of $94+ is realistic, perhaps as soon as the company declares its price for commercial sale of remdesivir," Porges wrote in a note to investors.Porges expects Gilead to price remdesivir at around $5,000 for a course of treatment, at the list price in the U.S.Overall, the stock has a Hold analyst consensus based on 15 recent Hold ratings, vs 9 Buy ratings and 4 Sell ratings. Meanwhile, the $79.95 average price target  is less optimistic than Porges’ as it indicates a mere 4.2% upside potential in the shares in the coming 12 months. (See Gilead stock analysis on TipRanks) Related News: Emergent Bio Plunges 14% Post-Market After Directors Divest Shares Teva Wins Court Ruling Against Opiant, Emergent Bio On Narcan Nasal Spray 5 Promising Covid-19 Vaccines Picked For Trump’s Operation Warp Speed More recent articles from Smarter Analyst: * Emergent Bio Plunges 14% Post-Market After Directors Divest Shares * AbbVie Announces Partnership To Develop Novel Covid-19 Antibody Therapy * PG&E; Is Said To Ready $11 Billion Debt Financing Plan * Teva Wins Court Ruling Against Opiant, Emergent Bio On Narcan Nasal Spray

from Yahoo Finance https://ift.tt/3dEKuUQ

Yahoo Finance’s Emily McCormick joins The First Trade to break down Gap’s response to a lawsuit filed by the mall owner Simon Property Group against the retailer.

from Yahoo Finance https://ift.tt/2UjdCte